AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 32 min read$RVTY

Revvity tops Q3 earnings and revenue estimates, sets FY2026 outlook (RVTY:NYSE)

Revvity (RVTY) reported Q3 Non-GAAP EPS of $1.38, beating estimates by $0.08, with revenue of $729M, up 4.3% Y/Y and exceeding expectations by $34.26M. The company provided FY2026 guidance, targeting EPS of $5.40–$5.45 and revenue of $2.86B, both above consensus.

Original reporting
seekingalpha.com
Published Nov 3, 2026, 11:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RVTY
Bullish
high confidence
Mentioned
$RVTY
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$RVTYBullishHigh
01

Why it matters

The earnings beat and upgraded guidance are likely to drive short‑term buying interest, especially from investors focused on the diagnostics sector.

02

Market read

The fresh earnings data provides a clear catalyst for RVTY and may influence related med‑tech stocks.

03

What to watch

Potential headwinds from supply‑chain constraints or upcoming regulatory reviews could temper upside.

Relevance 8/10Novelty 8/10Timing: post‑market release

Background

Revvity (RVTY) reported Q3 2026 results, beating earnings and revenue estimates and raising FY2026 guidance.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

Q3 Non‑GAAP EPS of $1.38 beat estimates and FY2026 guidance of $5.40‑$5.45 topped consensus, providing fresh earnings and outlook data.

Expected impact

likely upward pressure as investors price in the beat and higher guidance

Evidence & confidence

Both EPS and revenue exceeded expectations and FY guidance is above consensus, a classic catalyst for a price rally.

Market effects

Sector

Positive for the broader diagnostics and life‑sciences equipment sector as Revvity's beat may lift peers.

Regional

U.S. market may see modest gains in health‑tech stocks following the release.

Global

Limited to investors tracking U.S. med‑tech equities; no direct global macro effect.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑covering pull‑back.

Key entities

  • company
    Revvity, Inc.

    U.S. listed diagnostics and life‑science equipment provider.

Read at source← All news

StoryRevvity beats Q3 expectations and raises 2026 guidance

Also covered by

3 outlets

Related articles

NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Shares Jump After Strong Q3, Raises Outlook

Revvity shares rose 8.8% premarket after Q3 2026 earnings beat expectations, with adjusted EPS at $1.37 and revenue at $729M. The company raised FY 2026 guidance, targeting $5.40–$5.45 EPS and $2.86B revenue. Life Sciences segment grew 11%, and operating margin improved to 13.1%. CEO attributed results to strong execution. TD Cowen raised its price target to $175 in October.

tradingpedia.com2 min
NOV 3
$RVTYHighAI 8/10

Revvity Announces Financial Results for the Third Quarter of 2026

REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;

SEC EDGAR 8-K2 min